New combo therapy offers hope for Hard-to-Treat breast cancer
NCT ID NCT06434064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining tamoxifen (a hormone blocker) with a targeted form of chemotherapy (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. The trial enrolls 30 adults who have already tried at least two other treatments and have a specific TP53 gene change. The goal is to see how well the combination works and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer